Genfit : Echec d’elafibranor dans la NASH
>Des résultats décevants, des questions en suspens - Nous sommes dorénavant fixés et malheureusement les résultats se révèlent non concluants. Hier soir, Genfit a publié ses résultats de phase 3 RESOLVE-IT évaluant son composé phare elafibranor dans le traitement de la NASH. Le critère primaire n’a pas été atteint à savoir la résolution de la NASH sans aggravation de la fibrose. Le taux de réponse observé dans le bras composé des 717 patients ayant reçu elafibranor 12...Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.